M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy PharmaphorumNovo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence.NeuroscienceRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) Pharmaphorum Novo Nordisk has sold the rights to one of the flagship candidates in its now-defunct cell therapy unit to AI start-up Cellular Intelligence. Neuroscience Read full story Post navigation Previous: Third Circuit Affirms Denial of Stelara Biosimilar InjunctionNext: Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
